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Endobronchial Ultrasound-guided Transbronchial Needle 
Biopsy for Diagnosis of Mediastinal Lymphadenopathy in 
Patients with Extrathoracic Malignancy
Mediastinal lymphadenopathy associated with extrathoracic malignancy or a metastasis of 
unknown origin (MUO) requires pathological verification. Surgical exploration or 
endoscopic ultrasound-guided fine needle aspiration is limited to application. We 
investigated the effectiveness of endobronchial ultrasound-guided transbronchial needle 
biopsy (EBUS-TBNA) for evaluating mediastinal lymphadenopathy in patients with an 
extrathoracic malignancy. We retrospectively analyzed data from 59 patients who 
underwent EBUS-TBNA with a core biopsy because of a suspected mediastinal metastasis 
between September 2008 and August 2010. All patients had previously been diagnosed 
with an extrathoracic malignancy (n = 39, 66.1%) or a suspected MUO without a thoracic 
lesion (n = 20, 33.9%). A total of 88 lymph nodes was analyzed. EBUS-TBNA findings 
indicated malignancies in 34 patients (57.6%). The EBUS-TBNA sensitivity and specificity 
for the detection of mediastinal malignancy in patients with a previous extrathoracic 
malignancy were 96.3% and 100%, respectively. For MUO patients without a thoracic 
lesion, the sensitivity and specificity were 61.5% and 100%, respectively. The overall 
sensitivity and specificity were 81.0% and 100%, respectively (P = 0.053). EBUS-TBNA is a 
safe and effective modality for evaluating mediastinal lymphadenopathy in patients with a 
previous extrathoracic malignancy or a MUO without a thoracic lesion. The application of 
this diagnostic tool is likely to have significant clinical implications.
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INTRODUCTION
From the construction of a Korea National Cancer Incidence 
Database for 1999 onward to 2007, the completeness of the Ko-
rea Cancer Registry data has improved gradually. This might have 
contributed in part to the gradual overall increases in cancer in-
cidence, especially among the elderly. The cancer deaths account 
for about 27% of all deaths in Korea (1, 2).
  Patients treated for extrathoracic malignancies can subse-
quently develop a mediastinal lymphadenopathy. Accurate di-
agnosis of such mediastinal abnormalities is critical for effec-
tive treatment, and a pathological diagnosis should be made if 
possible (3, 4). 
  Although mediastinoscopy and open thoracic surgery are 
standard methods for mediastinal lymph node staging, they are 
invasive and costly. Endoscopic ultrasound-guided fine needle 
aspiration (EUS-FNA) is less invasive (5-7) but is limited in terms 
of access to some nodes and the amount of tissue that can be 
sampled.  
  Endobronchial ultrasound-guided needle aspiration (EBUS−
TBNA) and biopsy is a minimally invasive procedure that can 
be used for diagnosing mediastinal lymphadenopathy (8). The 
procedure shows high sensitivity, specificity, and diagnostic ac-
curacy for evaluating enlarged hilar or mediastinal lymph nodes 
possibly harboring malignancy (9). EBUS−TBNA has recently 
been declared a method for lung cancer surgical staging. Few 
studies have examined the effectiveness of EBUS−TBNA in iden-
tifying mediastinal spread in patients with current or previously 
diagnosed extrathoracic malignancies. 
  We investigated the effectiveness of EBUS-TBNA for evaluat-
ing mediastinal lymphadenopathy in patients diagnosed previ-
ously with extrathoracic malignancy or suspected metastatic 
cancer of unknown primary site (MUO) without a thoracic le-
sion. 
MATERIALS AND METHODS
Study subjects 
Between September 2008 and August 2010, 777 patients under-
went endobronchial ultrasound studies for a variety of clinical Park J, et al.  •  EBUS for Extrathoracic Malignancy
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indications at the Asan Medical Center. We retrospectively ana-
lyzed the data from 59 patients who underwent EBUS-TBNA 
with core biopsy. The patients underwent EBUS-TBNA because 
of a suspected mediastinal metastasis according to computed 
tomography (CT) (short axis > 1 cm) or fluorine 18-labelled de-
oxyglucose positron emission tomography (F-18 FDG PET). All 
patients had been diagnosed previously with an extrathoracic 
malignancy (n = 39, 66.1%) or a suspected MUO without a tho-
racic lesion (n = 20, 33.9%). There were 40 (67.8%) male patients, 
and the median age was 62.8 yr (range 20-81 yr). 
EBUS-TBNA procedure
The EBUS-TBNA procedures were performed by the same in-
terventional pulmonologist. Patients were placed in a conscious 
sedated state with midazolam. A standard conventional flexible 
bronchoscopy (model BF-T160 bronchoscope, Olympus, Tokyo, 
Japan) was first used to examine the tracheobronchial tree. A 
linear array ultrasonic bronchoscope (XBF-UC 160F; Olympus) 
with a dedicated 22-gauge needle (NA-202C, Olympus) was sub-
sequently used to perform the ultrasonic examination, trans-
bronchial aspiration and core biopsy. The regional lymph node 
stations of the mediastinum and hilar regions were imaged sys-
tematically and measured (short axis diameter) using the inter-
national staging system (Mountain classification). All imaged 
lymph nodes > 0.5 cm were sampled using real-time ultrasonic 
needle guidance. Doppler ultrasound was used to identify ves-
sels as necessary. The aspirated material was expelled onto glass 
slides, smeared, fixed immediately with 95% alcohol, and stained 
using hematoxylin-eosin (HE) and Papanicolaou stain. Tissue 
cores (obtained using EBUS-TBNA) were fixed with 10% neutral-
buffered formalin and stained using HE. Immunohistochemical 
staining was also performed when considered necessary. Rapid 
onsite cytopathological examination was not performed. Patients 
diagnosed with benign lymphadenopathy by EBUS-TBNA sub-
sequently underwent surgical staging of the mediastinum or 
clinical and radiological follow-up for at least 6 months. 
Data analysis
The primary endpoint was determining the diagnostic yield of 
EBUS-TBNA. The final diagnoses were based on the pathologi-
cal findings, clinical symptoms, serological tests, clinical follow-
up and, if available, surgical pathology. The sensitivity was com-
pared using the Kendall’s tau-b correlation coefficient. A two-
tailed P value of less than 0.05 was considered to be significant. 
Statistical analysis was carried out using the Statistical Package 
for the Social Sciences (version 14; SPSS Inc., Chicago, IL, USA).
Ethics statement
Because of retrospective analysis after having finished treatment, 
this study was approved by the institutional review board of the 
Asan Medical Center without informed consent (2010-0259).
 
RESULTS
The median mediastinal lymph node size detected with EBUS-
TBNA was 15 mm (range 5-50 mm). The median number of nee-
dle passages into a node was three (range 1-6). More than half 
of the EBUS-TBNA samples were from the right lower paratra-
cheal (n = 25, 28.4%) and subcarinal (n = 20, 22.7%) lymph nodes 
(Table 1). A total of 88 lymph nodes were analyzed using both 
Table 1. Characteristics of patients who had extrathoracic cancer with mediastinal 
lymphadenopathy
Parameters
 Previously  
diagnosed  
extrathoracic 
 malignancy
Newly diagnosed 
extrathoracic 
malignancy
 Total
No. of patients    39 (66.1%)    20 (33.9%) 59
Male    25 (64.1%)    15 (75.0%)    40 (67.8%)
Age* (yr) 59.9 (35-75) 67.3 (20-81) 62.8 (20-81)
EBUS-TBNA site
   4R
   4L
   7
   10R
   2R
   8
   11R
   11L
   12R
   12L
   Paratracheal lesion
56
   16 (28.6%)
   4 (7.1%)
   13 (23.2%)
   4 (7.1%)
   5 (8.9%)
   1 (1.8%)
     6 (10.7%)
   1 (1.8%)
0 (0%)
   1 (1.8%)
   5 (8.9%)
32
     9 (28.1%)
     4 (12.5%)
     7 (21.9%)
   3 (9.4%)
   3 (9.4%)
   2 (6.3%)
0 (0%)
   1 (3.1%)
   1 (3.1%)
0 (0%)
   2 (6.3%)
88
   25 (28.4%)
   8 (9.1%)
   20 (22.7%)
   7 (8.0%)
   8 (9.1%)
   3 (3.4%)
   6 (6.8%)
   2 (2.3%)
   1 (1.1%)
   1 (1.1%)
   7 (8.0%)
Node size (mm)* 15 (3-40) 20 (5-50) 15 (2-50)
No. of passage* 3 (1-4) 3 (2-6) 3 (1-6)
Data represent median (range) where indicated with an *, and otherwise represent num-
ber (%). TBNA, transbronchial needle aspiration; R, right; L, left.
Table 2. Comparison with EBUS-TBNA and final results in patients with a previously 
diagnosed extrathoracic malignancy
Previously diagnosed  
   extrathoracic  
   malignancy
EBUS results Final diagnosis
Test positive 
(n = 26)
Test negative 
(n = 13)
True positive 
(n = 27)
True negative   
(n = 12)
Colon cancer 5  3*  6
† 2
HCC 4 3 4 3
RCC 6 0 6 0
Breast cancer 4 2 4 2
H&N cancer 1 1 1 1
Esophageal cancer 0 2 0 2
Thyroid cancer 1 0 1 0
Thymic carcinoma 1 0 1 0
Prostate cancer 1 0 1 0
Pancreas cancer 0 1 0 1
Neuroblastoma 1 0 1 0
Melanoma 1 0 1 0
Lymphoma 1 0 1 0
AGC 0 1 0 1
The cancer type of each lymphadenopathy was same between test positive and true 
positive, except to the case of colon cancer. *were composed of sarcoidosis, thyroid 
cancer, and no tumor; 
†were composed of 5 colon cancer and 1 lung cancer. HCC, 
hepatocelluar carcinoma; RCC, renal cell carcinoma; H&N, head and neck; AGC, 
advanced gastric cancer; LN, lymph node.Park J, et al.  •  EBUS for Extrathoracic Malignancy
276   http://jkms.org DOI: 10.3346/jkms.2011.26.2.274
fine needle aspiration cytology and core biopsy. Three patients 
had a false negative result in the cytology despite a positive re-
sult in the core biopsy. It was possible to determine the origins 
of metastatic cancers in only seven of 31 patients using the cy-
tology findings. In contrast, the origins could be determined in 
30 of 34 patients when using the core biopsy findings. There 
were no procedure-related complications. 
  The EBUS-TBNA findings indicated that 34 (57.6%) of the 59 
patients were positive for malignancy (Tables 2, 3). Two of these 
34 patients were diagnosed with a cancer different from their 
previous colon cancer: one patient was newly diagnosed with a 
squamous cell lung cancer, and the other patient was diagnosed 
with thyroid papillary carcinoma. 
  The EBUS-TBNA findings indicated that 25 of the 59 patients 
were negative for malignancy. Four of these 25 patients under-
went surgical staging of the mediastinum, which identified me-
diastinal metastases in one patient, sclerosing mediastinitis in 
one patient, Castleman’s disease in one patient, and a reactive 
lymph node with negative PET in one patient. Three of the 21 
patients underwent excisional biopsy for a neck node. Two of 
the 21 patients showed progressive mediastinal disease radio-
logically without tissue confirmation and this was considered 
tumor positive. For the remaining 19 patients, no mediastinal 
malignancy was detected during a clinical and radiological me-
dian follow-up of 8.1 months (range 2.5-19.8 months).
  Ultimately, 40 of the 59 patients were found to have medias-
tinal metastases using any diagnostic tools. The sensitivity and 
specificity of EBUS-TBNA for the detection of mediastinal recur-
rence in patients with a previous extrathoracic malignancy were 
96.3% and 100%, respectively. For the detection of mediastinal 
malignancy in MUO patients, the sensitivity and specificity were 
61.5% and 100%, respectively (Table 4). The overall sensitivity 
and specificity were 81.0%, and 100%, respectively. The sensi-
tivity of EBUS was higher for mediastinal adenopathy with ex-
trathoracic malignant than for MUO (P = 0.053).
 
DISCUSSION
This study investigated the effectiveness of EBUS-TBNA in the 
detection of mediastinum metastases in patients with a suspect-
ed mediastinum metastasis who had previously been diagnosed 
with extrathoracic malignancy or MUO without a thoracic lesion. 
We found that for the whole study population, EBUS-TBNA had 
a high diagnostic sensitivity (81%) and specificity (100%). This 
sensitivity (96.3%) was even higher in the subgroup of patients 
with a previous extrathoracic malignancy (P = 0.053). There were 
no complications associated with the use of EBUS-TBNA.
  The most important indications for EBUS-TBNA are medias-
tinal staging for surgical resectability or restaging after chemo-
therapy or chemoradiation of non-small-cell lung cancer (NSCLC). 
EBUS-TBNA can also be used to diagnosis a lung mass, medias-
tinal lymphadenopathy or unknown mediastinopathy, regard-
less of the presence of an extrathoracic malignancy (8). To date, 
most studies (10, 11) of EBUS-TBNA have focused on mediasti-
nal staging or restaging, except for the study by Tournoy et al. 
(12). It is important to diagnose metastases with other causes 
beside lymphadenopathy such as granulomatous inflammation 
or infections, and treatable occult malignancies. Chow et al. (13) 
reported on a case where EBUS-TBNA was used to diagnose an 
enlarged metastatic mediastinal lymph node caused by an un-
identified primary papillary thyroid carcinoma. Hamamoto et 
al. (14) described a case of epithelioid malignant pleural meso-
thelioma diagnosed using EBUS-TBNA. After a retrospective 
chart review, Kennedy et al. (15) reported that 10 of 25 patients 
with suspected mediastinal recurrences of lymphoma or medi-
astinal lymphadenopathy of unknown cause were diagnosed 
with lymphomas using EBUS-TBNA.
  EBUS-TBNA is a relatively new modality for sampling medi-
astinal lymph nodes. Earlier studies of its application in medi-
astinal staging or restaging of NSCLC showed high diagnostic 
rates for EBUS-TBNA, with sensitivity and positive predictive 
values of more than 90% and specificity of 100% (16-18). These 
values are similar to the present findings. Tournoy et al. (12) re-
ported that sensitivity for mediastinal or hilar metastatic spread 
of 85%. Kennedy et al. (15) reported that use of EBUS-TBNA to 
diagnose mediastinal lymphadenopathy in suspected lympho-
ma cases yielded a high false negative rate (10 of 12 patients). 
Table 3. Comparison of EBUS-TBNA with final results in suspected metastatic of 
unknown primary site without thoracic lesion
EBUS TBNA results  No. Final diagnosis  No.
Benign 12 Negative 1
Sclerosing mediastinitis 1
Castleman’s disease 1
Choroidal melanoma 1
Colon cancer 1
GB cancer 1
MUO 1
Lymphoma 3
Pancreatic cancer 1
Thyroid cancer 1
Malignant   8 HCC 1
Lymphoma 3
Sarcoma 1
Seminoma 1
Thyroid cancer 1
AGC 1
GB, gall bladder; MUO, metastatic cancer of unknown primary site; HCC, hepatocelluar 
carcinoma; AGC, advanced gastric cancer.
Table 4. Diagnostic performance characteristics of EBUS-TBNA
    Prior  
    malignancy
    Primary  
    evaluation
    Total
P 
value
Sensitivity      96.3%      61.5%      81.0% 0.053
Specificity      100%       100%       100%Park J, et al.  •  EBUS for Extrathoracic Malignancy
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Fig. 1. Histologic finding on EBUS-TBNA sample using tissue specific immunohistochemical stains. (A) Histologic findings breast cancer (H&E stain, × 100) with (a) positive ER 
stains (× 200), (B) hepatocelluar carcinoma (H&E stain, ×200) with (b) positive CK stain (×400), (C) malignant melanoma including brownish pigments (H&E stain, × 200) with 
(c) positive S100 stains (× 400), and (D) renal cell carcinoma cells (H&E stain, × 100) with (d) positive CD10 stains (× 200). EBUS-TBNA, endobronchial ultrasound-guided 
transbronchial needle aspiration.
Peric et al. (19) reported that in 75 patients with a previous ex-
trathoracic malignancy and suspected mediastinal metastases, 
EUS-FNA demonstrated a high sensitivity (86%) (19, 20). Kramer 
et al. (5) assessed 20 patients with mediastinal lymphadenopa-
thy and previous extrathoracic malignancy, and reported that 
the sensitivity and specificity of EUS-FNA were 69% and 100%, 
respectively. In our study, the overall sensitivity and specificity 
were 81.0%, and 100%, respectively. The sensitivity was higher in 
non-MUO cases than in MUO cases (96.3% vs 61.5%, P = 0.053).
  This is the study to examine the effectiveness of EBUS-TBNA 
with a focus on mediastinal lymphadenopathy in patients with 
extrathoracic malignancy. In previous extrathoracic malignan-
cy cased, the sensitivity and specificity of EBUS-TBNA were high-
er than the figures reported for EUS-FNA (6, 21, 22). 
  One likely reason for this is that EBUS-TBNA allows access to 
more lymph nodes compared with EUS-FNA. In addition, EBUS-
TBNA samples can undergo histology diagnosis, including im-
munohistochemistry (23, 24) (Fig. 1). The current findings indi-
cate that EBUS-TBNA was as effective in the present cohort as it 
is in lung cancer patients.
  The present study had several limitations. The study was ret-
rospective in design, involved a relatively small number of pa-
tients, and had an unavoidable selection bias.
  In conclusion, EBUS-TBNA is found to be a safe, simple and 
effective procedure. In particular, EBUS-TBNA is effective for 
assessing mediastinal abnormalities in patients with a history 
of extrathoracic malignancy. It is concluded that EBUS-TBNA 
may be a good initial tissue sample test to establish a tissue di-
agnosis in patients with suspected mediastinal involvement. 
REFERENCES
1. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS. 
Cancer Statistics in Korea: Incidence, Mortality and Survival in 2006-
2007. J Korean Med Sci 2010; 25: 1113-21.
2. Jung KW, Won YJ, Park S, Kong HJ, Sung J, Shin HR, Park EC, Lee JS. 
Cancer statistics in Korea: incidence, mortality and survival in 2005. J 
Korean Med Sci. 2009; 24: 995-1003.
3. Mahon TG, Libshitz HI. Mediastinal metastases of infradiaphragmatic 
malignancies. Eur J Radiol 1992; 15: 130-4.
4. Whooley BP, Urschel JD, Antkowiak JG, Takita H. Primary tumors of the 
mediastinum. J Surg Oncol 1999; 70: 95-9.
5. Kramer H, Koëter GH, Sleijfer DT, van Putten JW, Groen HJ. Endoscopic Park J, et al.  •  EBUS for Extrathoracic Malignancy
278   http://jkms.org DOI: 10.3346/jkms.2011.26.2.274
ultrasound-guided fine-needle aspiration in patients with mediastinal 
abnormalities and previous extrathoracic malignancy. Eur J Cancer 
2004; 40: 559-62.
6. Fritscher-Ravens A, Sriram PV, Bobrowski C, Pforte A, Topalidis T, Krause 
C, Jaeckle S, Thonke F, Soehendra N. Mediastinal lymphadenopathy in 
patients with or without previous malignancy: EUS-FNA-based differen-
tial cytodiagnosis in 153 patients. Am J Gastroenterol 2000; 95: 2278-84.
7. Kim H, Chung SJ, Kim SG, Kim JS, Jung HC, Song IS. Endoscopic ultra-
sonography-guided fine needle aspiration for computed tomography-
negative and positron emission tomography-positive mediastinal lymph 
node in a patient with recurrent lung cancer. Gut Liver 2007; 1: 90-2.
8. Cameron SE, Andrade RS, Pambuccian SE. Endobronchial ultrasound 
guided transbronchial needle aspiration cytology: a state of the art review. 
Cytopathology 2010; 21: 6-26.
9. Medford AR, Bennett JA, Free CM, Agrawal S. Endobronchial ultrasound 
guided transbronchial needle aspiration. Postgrad Med J 2010; 86: 106-15.
10. Herth FJ, Annema JT, Eberhardt R, Yasufuku K, Ernst A, Krasnik M, 
Rintoul RC. Endobronchial ultrasound with transbronchial needle aspi-
ration for restaging the mediastinum in lung cancer. J Clin Oncol 2008; 
26: 3346-50.
11. Lee JE, Kim HY, Lim KY, Lee SH, Lee GK, Lee HS, Hwangbo B. Endo-
bronchial ultrasound-guided transbronchial needle aspiration in the di-
agnosis of lung cancer. Lung Cancer 2010; 70: 51-6. 
12. Tournoy KG, Govaerts E, Malfait T, Dooms C. Endobronchial ultrasound-
guided transbronchial needle biopsy for M1 staging of extrathoracic ma-
lignancies. Ann Oncol 2011; 22: 127-31.
13. Chow A, Oki M, Saka H, Moritani S, Usami N. Metastatic mediastinal 
lymph node from an unidentified primary papillary thyroid carcinoma 
diagnosed by endobronchial ultrasound-guided transbronchial needle 
aspiration. Intern Med 2009; 48: 1293-6.
14. Hamamoto J, Notsute D, Tokunaga K, Sasaki J, Kojima K, Saeki S, Tana-
ka R, Tanaka H, Kohrogi H. Diagnostic Usefulness of Endobronchial Ul-
trasound-Guided Transbronchial Needle Aspiration in a Case with Ma-
lignant Pleural Mesothelioma. Intern Med 2010; 49: 423-6.
15. Kennedy MP, Jimenez CA, Bruzzi JF, Mhatre AD, Lei X, Giles FJ, Fanning 
T, Morice RC, Eapen GA. Endobronchial ultrasound-guided transbron-
chial needle aspiration in the diagnosis of lymphoma. Thorax 2008; 63: 
360-5.
16. Nakajima T, Yasufuku K, Iyoda A, Yoshida S, Suzuki M, Sekine Y, Shibuya 
K, Hiroshima K, Nakatani Y, Fujisawa T. The evaluation of lymph node 
metastasis by endobronchial ultrasound-guided transbronchial needle 
aspiration: crucial for selection of surgical candidates with metastatic 
lung tumors. J Thorac Cardiovasc Surg 2007; 134: 1485-90.
17. Sun W, Song K, Zervos M, Pass H, Cangiarella J, Bizekis C, Crawford B, 
Wang BY. The diagnostic value of endobronchial ultrasound-guided nee-
dle biopsy in lung cancer and mediastinal adenopathy. Diagn Cytopa-
thol 2010; 38: 337-42.
18. Ernst A, Eberhardt R, Krasnik M, Herth FJ. Efficacy of endobronchial ul-
trasound-guided transbronchial needle aspiration of hilar lymph nodes 
for diagnosing and staging cancer. J Thorac Oncol 2009; 4: 947-50.
19. Peric R, Schuurbiers OC, Veseliç M, Rabe KF, van der Heijden HF, 
Annema JT. Transesophageal endoscopic ultrasound-guided fine-needle 
aspiration for the mediastinal staging of extrathoracic tumors: a new 
perspective. Ann Oncol 2010; 21: 1468-71.
20. Iwashita T, Yasuda I, Doi S, Nakashima M, Tsurumi H, Hirose Y, Takami 
T, Enya M, Mukai T, Ohnishi T, Iwata K, Tomita E, Moriwaki H. Endo-
scopic ultrasound-guided fine-needle aspiration in patients with lymph-
adenopathy suspected of recurrent malignancy after curative treatment. 
J Gastroenterol 2009; 44: 190-6.
21. Catalano MF, Rosenblatt ML, Chak A, Sivak MV Jr, Scheiman J, Gress F. 
Endoscopic ultrasound-guided fine needle aspiration in the diagnosis of 
mediastinal masses of unknown origin. Am J Gastroenterol 2002; 97: 
2559-65.
22. Herth FJ, Krasnik M, Kahn N, Eberhardt R, Ernst A. Combined endo-
scopic-endobronchial ultrasound-guided fine-needle aspiration of medi-
astinal lymph nodes through a single bronchoscope in 150 patients with 
suspected lung cancer. Chest 2010; 138: 790-4.
23. Yasufuku K, Chiyo M, Koh E, Moriya Y, Iyoda A, Sekine Y, Shibuya K, Ii-
zasa T, Fujisawa T. Endobronchial ultrasound guided transbronchial nee-
dle aspiration for staging of lung cancer. Lung Cancer 2005; 50: 347-54.
24. Rintoul RC, Skwarski KM, Murchison JT, Wallace WA, Walker WS, Pen-
man ID. Endobronchial and endoscopic ultrasound-guided real-time 
fine-needle aspiration for mediastinal staging. Eur Respir J 2005; 25: 
416-21.
AUTHOR SUMMARY
Endobronchial Ultrasound-guided Transbronchial Needle Biopsy for Diagnosis of 
Mediastinal Lymphadenopathy in Patients with Extrathoracic Malignancy
Jinkyeong Park, Se Jin Jang, Young Soo Park, Yeon Mok Oh, Tae Sun Shim, Woo Sung Kim, and Chang Min Choi
EBUS-TBNA is a safe and effective modality (81% sensitivity and 100% specificity) for evaluating mediastinal lymphadenopathy in 
patients with a previous extrathoracic malignancy or a MUO without a thoracic lesion.